At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 274 enrolled
Drug / intervention
Nemolizumab +1 moredrug
Likely dose
Nemolizumab 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis
In Brief
A Phase 3 clinical trial evaluating Nemolizumab and Placebo for Prurigo Nodularis. Completed, enrolled 274 participants across 74 sites in 9 countries.
Detailed Summary
The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (\>=) 18 years of age with prurigo nodularis (PN) after a 16-week treatment period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrurigo Nodularis
CountriesBelgium, Canada, France, Netherlands, Poland, South Korea, Spain, Switzerland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartAug 2020
Primary CompletionMar 2022
Study CompletionMar 2022
TodayJul 2026
First PostedAug 6, 2020
Enrollment StartAug 11, 2020
Primary CompletionMar 30, 2022
Study CompletionMar 31, 2022
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 5.9 years ago
Interventions
Nemolizumabdrug
Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection.
Placebodrug
Participants received matching placebo as SC injection.